Literature DB >> 30091445

Insulin resistance indexes in women with premature ovarian insufficiency - a pilot study.

Michał Kunicki, Ewa Rudnicka, Jolanta Skórska, Anna Izabela Calik-Ksepka1, Roman Smolarczyk.   

Abstract

OBJECTIVES: Premature ovarian insufficiency (POI) is associated with hypoestrogenism and an increased risk of metabolic disorders. In many clinics, a variety of insulin resistance (IR) tests are used during routine clinical assessments. To date, there is no clear opinion about which of these tests should be applied in women with premature ovarian insufficiency (POI). Therefore, our preliminarily aim was to compare the most frequently used insulin resistance indexes in the clinical assessment of a group of POI women and a control group.
MATERIAL AND METHODS: Our retrospective study included 98 women with karyotypically normal spontaneous POI aged 18-39 years and a control group of 78 healthy women. Each patient was given an oral glucose tolerance test (OGTT) to evaluate their insulin release and insulin resistance. In addition, each woman's insulin resistance (IR) was evaluated us-ing the homeostasis model assessment for insulin resistance (HOMA-IR), the quantitative insulin sensitivity check index (QUICKI), the fasting glucose-to-insulin ratio (FGIR), and Matsuda and McAuley indexes. The two groups' glucose levels were compared at 0, 60 and 120 min of the OGTT.
RESULTS: At 0 and 60 min of the OGTT, the insulin levels of the POI women were significantly higher than those of the control group. The number of women in whom IR was detected using the various kits was comparable between the two groups. CONLUSIONS: In conclusion, only the OGTT evaluation revealed a significant difference in insulin concentrations between the two study groups. The indexes most commonly used to detect IR did not detect differences in IR between the POI women and the members of the healthy control group. QUICKI detected significantly more women with IR within both study groups than other tests did.

Entities:  

Keywords:  insulin resistance; premature ovarian insufficiency

Mesh:

Substances:

Year:  2018        PMID: 30091445     DOI: 10.5603/GP.a2018.0062

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  5 in total

1.  CCR2/CCL2 and CMKLR1/RvE1 chemokines system levels are associated with insulin resistance in rheumatoid arthritis.

Authors:  Gustavo Ignacio Diaz-Rubio; Fernanda-Isadora Corona-Meraz; Perla-Monserrat Madrigal-Ruiz; Jesús-Aureliano Robles-De Anda; Eduardo Gómez-Bañuelos; Jorge Castro-Albarran; Luis-Javier Flores-Alvarado; Mónica Vázquez-Del Mercado; Felipe de Jesús Pérez-Vázquez; Oscar-Enrique Pizano-Martínez; Rosa-Elena Navarro-Hernández
Journal:  PLoS One       Date:  2021-01-28       Impact factor: 3.240

2.  Network Pharmacology Approach for Predicting Targets of Zishen Yutai Pills on Premature Ovarian Insufficiency.

Authors:  Yihui Feng; Xinyi Chai; Yingyin Chen; Yan Ning; Ying Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-04       Impact factor: 2.629

3.  Does the Value of FSH Predict Severity of Metabolic Complications in Females with POI?

Authors:  Michał Kunicki; Jagoda Kruszewska; Jolanta Skórska; Hanna Laudy-Wiaderny; Marcin Wrona; Roman Smolarczyk
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

Review 4.  Metabolic differences in women with premature ovarian insufficiency: a systematic review and meta-analysis.

Authors:  Wang-Yu Cai; Xi Luo; Wei Wu; Jianyuan Song; Ning-Ning Xie; Cuicui Duan; Xiao-Ke Wu; Jian Xu
Journal:  J Ovarian Res       Date:  2022-09-30       Impact factor: 5.506

5.  Insulin Resistance, Serum Calcium and Hypertension: A Cross-Sectional Study of a Multiracial Population, and a Similarity Assessment of Results from a Single-Race Population's Study.

Authors:  Victorine Raïssa Ngo Nkondjock; Thérèse Martin Cheteu Wabo; Janet Cheruiyot Kosgey; Yunlong Zhang; Daniel Adjei Amporfro; Humara Adnan; Imran Shah; Ying Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-24       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.